These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 11974678

  • 1. FDA approves NuvaRing contraceptive implant.
    J Gend Specif Med; 2002; 5(2):6. PubMed ID: 11974678
    [No Abstract] [Full Text] [Related]

  • 2. Introduction. NuvaRing.
    Milsom I.
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():11; discussion 37-9. PubMed ID: 12659396
    [No Abstract] [Full Text] [Related]

  • 3. Complete and robust ovulation inhibition with NuvaRing.
    Killick S.
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():13-8; discussion 37-9. PubMed ID: 12659397
    [Abstract] [Full Text] [Related]

  • 4. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
    Ahrendt HJ, Nisand I, Bastianelli C, Gómez MA, Gemzell-Danielsson K, Urdl W, Karskov B, Oeyen L, Bitzer J, Page G, Milsom I.
    Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [New forms of hormonal contraception].
    Gaspard U, Buicu C, van den Brûle F.
    J Gynecol Obstet Biol Reprod (Paris); 2000 May; 29(3):288-91. PubMed ID: 10804374
    [Abstract] [Full Text] [Related]

  • 7. Lower hormone dosage with improved cycle control.
    Vree M.
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():25-30; discussion 37-9. PubMed ID: 12659399
    [Abstract] [Full Text] [Related]

  • 8. The combined contraceptive vaginal device (NuvaRing): a comprehensive review.
    Sarkar NN.
    Eur J Contracept Reprod Health Care; 2005 Jun; 10(2):73-8. PubMed ID: 16147810
    [Abstract] [Full Text] [Related]

  • 9. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone.
    Milsom I, Lete I, Bjertnaes A, Rokstad K, Lindh I, Gruber CJ, Birkhäuser MH, Aubeny E, Knudsen T, Bastianelli C.
    Hum Reprod; 2006 Sep; 21(9):2304-11. PubMed ID: 16763008
    [Abstract] [Full Text] [Related]

  • 10. The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage.
    Verhoeven CH, Dieben TO.
    Contraception; 2004 Mar; 69(3):197-9. PubMed ID: 14969666
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability.
    Novák A, de la Loge C, Abetz L, van der Meulen EA.
    Contraception; 2003 Mar; 67(3):187-94. PubMed ID: 12618252
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Assessment of Implanon insertion and removal.
    Levine JP, Sinofsky FE, Christ MF, Implanon US Study Group.
    Contraception; 2008 Nov; 78(5):409-17. PubMed ID: 18929739
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.